Executive Profile

Magnus Persson M.D., Ph.D. Former Director, ChemoCentryx, Inc.

Age	Total Calculated Compensation	This person is connected to 7 Board Members in 7 different organizations across 15 different industries. See Board Relationships
--	--

Background

Dr. Magnus Persson, M.D., Ph.D. has been a Director of AOI Medical, Inc. since February 2012. Dr. Persson serves as a Director of AscendxSpine and Sjalbadan. He also serves as a Director of Swedish Center for Medical Nanotechnology at Karolinska Institute. He served as a Member of Supervisory Board at Trigen Holdings AG since April 2005. Dr. Persson has been a Director or Board Observer of companies such as ChemoCentryx, FivePrime Therapeutics, PTC Therapeutics, Cerecor, ... Inc. since August 31, 2012, ConcitPharma, and Lumavita AG. He had been Managing Partner of The Column Group LLC. since January 1, 2010. Dr. Persson joined The Column Group on January 1, 2010. He has 15 years of Partner level experience from Venture Capital and has been a Partner in two Life Sciences Venture Capital firms. Dr. Persson has a long experience in medicine, life sciences and biotech financing. He has led development teams of Phase II and III programs in the Pharmaceutical Industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board and Director in the Nordic Countries, Europe and USA. He has a vast international network in the science and biotech financing communities. Dr. Persson served as a Partner of HealthCap for thirteen years, which he joined in 1996. Dr. Persson served as a Clinical Research Physician at Sanofi Winthrop. He served at the Neonatal Intensive Care Unit at the Karolinska Hospital during several periods. Dr. Persson serves as the Chairman of SLS Invest. He served as an Acting Chairman of Immune Targeting Systems (ITS) Limited until September 2012. He served as a Director of Alba Therapeutics Corp., Chemocentry, Inc., ChronTech Pharma AB, PTC Therapeutics, Inc., TopoTarget Switzerland S.A., SpineVision Inc., Carmot Therapeutics, Inc., MIPS Technologies, Inc., Lica Pharmaceuticals A/S, IDEA, Neoventa Medical AB, and Prolifix. He served as a Director of Arpida AG until April 2006. He served as a Lecturer and Associate Professor in Physiology at the Karolinska Institute. Dr. Persson pursued scientific research and is the Author of 37 scientific articles on cardiovascular, pulmonary, and gastrointestinal physiology. Dr. Persson is a licensed doctor. In 1991, he published his thesis and has a Ph.D. degree in Physiology. Dr. Persson also holds an M.D. at the Karolinska Institute in 1986 and at Harvard Medical School.

Corporate Headquarters 1700 Owens Street San Francisco, California 94158 United States Phone: 415-865-2050 Fax: 415-255-2048 Board Members Memberships Former Director MIPS Technologies, Inc. Former Director Arpida AG Director Neoventa Medical AB Former Director ChemoCentryx, Inc. Director Lica Pharmaceuticals A/S Former Director PTC Therapeutics, Inc. Director of Swedish Center for Medical Nanotechnology Karolinska Institutet Chairman of the Board SLS Invest Director TopoTarget Switzerland S.A. Former Director Alba Therapeutics Corporation Former Non-Executive Director Trigen Holdings AG Director ChronTech Pharma AB Director Immune Targeting Systems (ITS) Limited Director SpineVision, Inc. Director Lumavita AG Director Carmot Therapeutics, Inc. Director Concit Pharma ApS 2012-Present Director AOI Medical, Inc. 2012-Present Director Cerecor, Inc. Education MD 1986 Karolinska Institutet MD Harvard Medical School Other Affiliations MIPS Technologies, Inc. HealthCap Arpida AG Neoventa Medical AB Lica Pharmaceuticals A/S PTC Therapeutics, Inc. Karolinska Institutet SLS Invest Harvard Medical School TopoTarget Switzerland S.A. Sanofi Winthrop Inc. Alba Therapeutics Corporation Trigen Holdings AG The Column Group LLC ChronTech Pharma AB AOI Medical, Inc. Immune Targeting Systems (ITS) Limited SpineVision, Inc. Lumavita AG Carmot Therapeutics, Inc. Concit Pharma ApS Cerecor, Inc.

Annual Compensation There is no Annual Compensation data available. Stocks Options There is no Stock Options data available. Total Compensation There is no Total Compensation data available.

COMPETITOR COMPENSATION

Name	Position/ Company	Compensation
George A. Scangos Ph.D.	Chief Executive Officer and Director Biogen Idec Inc.	$1.3M
G. Kelly Martin	Chief Executive Officer and Executive Director Elan Corporation, plc	$2.1M
Jeremy Levin D.Phil., MB, B.Chir	Chief Executive Officer and President Teva Pharmaceutical Industries Limited	--
Paul A. Friedman M.D.	Chief Executive Officer, President, Director, Member of Non-Management Stock Option Committee and Member of Finance Committee Incyte Corporation	$666.5K
Yasuchika Hasegawa	Chief Executive Officer, President and Representative Director Takeda Pharmaceutical Company Limited	--
Compensation as of Fiscal Year 2012.